Researchers are hopeful that this ‘ground-breaking approach’ could accelerate the prediction of which patients are more at risk of their disease returning
Syncona and Cancer Research Technology have announced the launch of a new private company – Achilles Therapeutics – that will bring together research from University College London and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research.